Sex hormones, insomnia, and sleep quality: subjective sleep in the first year of hormone use 139 Figure 5.1. The number of unique participants (n) per center and group, before and after applying exclusion criteria. Total n reflects the number of unique participants contributing to any measurement. 2.3. Gender-affirming hormone therapy Masculinizing hormones used by trans men consisted of testosterone gel (daily dose of 40.5mg), intramuscular testosterone esters (250mg every 3 weeks), or intramuscular testosterone undecanoate (1000mg every 12 weeks). For participants who reported persisting menstruation or intermittent menstrual blood loss, continued use of hormonal contraceptives (i.e. injectable medroxyprogesterone, subcutaneous implant containing etonogestrel, intra-uterine device containing levonorgestrel, or combined oral contraceptives) or use of progestogens as menstruation suppressants (lynestrenol, 5mg per day) was recommended. Use of menstruation suppressants and hormonal contraceptives in the trans men
RkJQdWJsaXNoZXIy MTk4NDMw